Track SMS Pharmaceuticals Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -4.88 %
Low
421.6
High
454.9
1 Month returns: 3.61 %
Low
393.3
High
494.5
1 Year returns: 54.08 %
Low
270.1
High
494.5
3 Year CAGR: 51.17 %
Low
111.8
High
494.5
5 Year CAGR: 23.17 %
Low
54.5
High
494.5
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for SMS Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
SMS Pharmaceuticals Ltd. Shareholding Pattern
Quarterly breakdown of SMS Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in SMS Pharmaceuticals Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of SMS Pharmaceuticals Ltd.?
The current share price of SMS Pharmaceuticals Ltd. is ₹ 424.95 as of 15 Oct 2026.
What is the market capitalisation of SMS Pharmaceuticals Ltd.?
The market capitalisation of SMS Pharmaceuticals Ltd. stands at ₹ 3,950.24 Cr.
What is the PE ratio of SMS Pharmaceuticals Ltd.?
The Price-to-Earnings (PE) ratio of SMS Pharmaceuticals Ltd. is 38.73 as of the latest trailing twelve months data.
What is the ROE and ROCE of SMS Pharmaceuticals Ltd.?
SMS Pharmaceuticals Ltd. has a Return on Equity (ROE) of 14.31% and a Return on Capital Employed (ROCE) of 12.50% as per the latest financial reports.
What is the 52-week high and low of SMS Pharmaceuticals Ltd.?
The 52-week high of SMS Pharmaceuticals Ltd. is - and the 52-week low is -.
What is the dividend yield of SMS Pharmaceuticals Ltd.?
The dividend yield of SMS Pharmaceuticals Ltd. is 0.09% based on the current market price.
What is the FII and DII holding in SMS Pharmaceuticals Ltd.?
Foreign Institutional Investors (FII) hold 1.18%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 28.71% of SMS Pharmaceuticals Ltd. shares.
What sector does SMS Pharmaceuticals Ltd. belong to?
SMS Pharmaceuticals Ltd. operates in the Healthcare sector.
What is the beta of SMS Pharmaceuticals Ltd.?
The beta of SMS Pharmaceuticals Ltd. is 1.16, indicating its price volatility relative to the broader market. Over the past 1 year, SMS Pharmaceuticals Ltd. has delivered an absolute return of 58.43%.
What is the RSI of SMS Pharmaceuticals Ltd.?
The 14-day Relative Strength Index (RSI) of SMS Pharmaceuticals Ltd. is 42.86, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
424.951.3 (0.31%)
55.07% in past 1 year
Stock Analysis
Fundamental analysis overview of SMS Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 76.2 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
76.2 / 100
Moderate ROE but improving trend
The company reported moderate ROE of 14.31% for 12-month ended 30 Jun 2026 but ROE improved by 254 bps from 1 year ago
What is ROE (FY)?
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 36.64% for 12-month ended 30 Jun 2026 and the growth was 29.19 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.46 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.03 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 5 financial years
What is Dividend streak?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 38.73 indicates that the stock is expensive on a standalone basis and is at a 22.52% premium to industry median P/E
What is P/E Ratio?
Median: 31.61
Value 38.73
-0.8705.79
Low dividend yield
The company has a low dividend yield of 0.09%
What is Dividend yield?
Neutral
Moderate and stable operating margin
The company reported moderate operating margin of 14.81% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 140 bps from 1 year ago
What is Operating profit margin?
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 10.25% for 12-month ended 30 Jun 2026 and the growth was 0.43 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 10.68
Value 10.25
-99.6111701.8
Company's earnings are of moderate quality
Earnings quality score of 41.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
41.8 / 100
No red flags found!
No significant red flags found in the stock.
Name
Month
Transaction
Holding % pre transaction
Average price
Qty.
Transaction value
N. Srilakshmi Padmini
Employees Immediate Relative
August-2026
Market Purchase (Acquisition)
24th Aug 2026
0.04 %
₹ 356.07
3.00 k
₹ 10.68 lac
P. Deepthi Sri
Employees Immediate Relative
June-2026
Market Sale (Disposal)
2nd Jun 2026
0.01 %
₹ 316.00
5.00 k
₹ 15.80 lac
P. Manideep
Employees Immediate Relative
March-2026
Market Sale (Disposal)
16th Mar 2026
0.03 %
₹ 385.00
1.00 k
₹ 3.85 lac
P. Manideep
Employees Immediate Relative
March-2026
Market Sale (Disposal)
16th Mar 2026
0.03 %
₹ 417.33
1.50 k
₹ 6.26 lac
G. Suresh Kumar
Director
February-2026
Market Sale (Disposal)
28th Feb 2026
0.02 %
₹ 395.63
5.00 k
₹ 19.78 lac
P. Srinivasa Rao
Employee
February-2026
Market Sale (Disposal)
28th Feb 2026
0.00 %
₹ 389.89
2.00 k
₹ 7.80 lac
P. Srinivasa Rao
Employee
February-2026
Market Sale (Disposal)
28th Feb 2026
0.00 %
₹ 395.16
3.01 k
₹ 11.88 lac
G. Suresh Kumar
Director
February-2026
Market Sale (Disposal)
24th Feb 2026
0.02 %
₹ 372.90
1.00 k
₹ 3.73 lac
G. Suresh Kumar
Director
February-2026
Market Sale (Disposal)
19th Feb 2026
0.02 %
₹ 369.80
1.12 k
₹ 4.14 lac
G. Suresh Kumar
Director
November-2025
Market Sale (Disposal)
28th Nov 2025
0.02 %
₹ 298.50
3.00 k
₹ 8.95 lac
Corporate Actions
History of SMS Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 0.40/share
Record date: 22nd Sep 2026Ex-date: 22nd Sep 2026
Announced on: 22nd May 2026
Dividend₹ 0.40/share
Record date: 22nd Sep 2025Ex-date: 22nd Sep 2025
Announced on: 30th May 2025
Dividend₹ 0.40/share
Record date: 23rd Sep 2024Ex-date: 23rd Sep 2024
Announced on: 29th May 2024
Dividend₹ 0.30/share
Record date: 22nd Sep 2023Ex-date: 22nd Sep 2023
Announced on: 24th May 2023
Dividend₹ 0.30/share
Record date: 23rd Sep 2022Ex-date: 22nd Sep 2022
Announced on: 30th May 2022
Company Profile
Overview of SMS Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, an...
Key personnel
Sri. Lakshmi Narayana Tammineedi
Chief Financial Officer
Mr. Thirumalesh Tumma
Chief Compliance Officer, Company Secretary
Shri. Ramesh Babu PotluriD
Executive Chairman of the Board, Managing Director